These results, along with the downregulation of several host genes involved in the immune response to SARS-CoV-2 (Gzma, Irf1, Stat1, Stat3), suggest that HFDs might be detrimental to COVID-19 patients (Fig. 7). The gene discussed is GZMA; the disease is COVID-19.